Abstract

We recently developed a computational tool (EczemaPred) for personalised prediction of AD severity dynamics using PO-SCORAD. We aim to investigate whether EczemaPred can be applied to predict POEM score recorded weekly. We used data from 247 AD patients aged 11 to 65 years in a dose-finding study with up to 6 measurements of POEM and daily symptom scores for POEM over 16 weeks. We investigated the influence of the recency bias in reporting POEM by computing the partial cross-correlation between the observed POEM score and daily symptom scores recorded on the previous seven days using linear mixed-effects models.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call